Juq-473 Now

When sourcing a JUQ-473, the market often offers "OEM" (Original Equipment Manufacturer) versions and "Generic" alternatives. Experts generally recommend the OEM path for this specific part. Because JUQ-473 is often a "mission-critical" component, a failure in a low-quality substitute can lead to:

| Patent family | Publication No. | Key claims | |----------------|----------------|------------| | US 11,894,321 (filed 2022) | US 2024/0187352 A1 | Claims a series of with a heterocyclic core identical to JU‑473; covers oral dosage forms up to 300 mg. | | WO 2023/067845 | WO 2025/012345 | Global protection for method of treating neuro‑degeneration using biased GPCR‑X agonists. | | US 2025/0145678 | US 2025/0145678 A1 | Combination therapy patents (JU‑473 + GLP‑1 agonist) – granted 2026 (US 11,950,112). | JUQ-473